HSV in Immunocompromised Patients — Special Considerations

HSV in people with weakened immune systems behaves differently than in immunocompetent people. Outbreaks are more frequent, more severe, sometimes resistant to first-line treatment, and occasionally disseminate beyond local areas.

If you're HIV+, transplant patient, or on chemotherapy/immunosuppressants — and you have HSV — here's what to know.

The short answer

  • More frequent outbreaks — sometimes monthly or worse
  • More severe lesions — slower healing, larger, more painful
  • Atypical presentations — chronic ulcers, not classic vesicles
  • Resistance more common — acyclovir resistance possible
  • Disseminated disease — rare but serious in severely immunocompromised
  • Higher transmission — asymptomatic shedding more frequent
  • Treatment — often higher dose, longer duration, sometimes IV
  • Suppressive therapy — typically recommended

Who counts as immunocompromised

Common scenarios

  • HIV — especially with CD4 < 200
  • Solid organ transplant (kidney, liver, heart, lung)
  • Hematologic stem cell transplant (bone marrow)
  • Chemotherapy — active or recent
  • Biologic medications — TNF inhibitors, JAK inhibitors, etc.
  • Long-term corticosteroids
  • DMARDs for autoimmune disease
  • Congenital immunodeficiency

HSV in HIV

Patterns

  • HSV-2 prevalence very high in HIV+ population
  • More frequent outbreaks (especially with low CD4)
  • More severe outbreaks
  • More asymptomatic shedding
  • Higher HIV transmission risk during HSV reactivation

Management

  • Suppressive antiviral often recommended
  • Acyclovir 400-800 mg twice daily
  • Or valacyclovir 500-1000 mg daily
  • Higher doses for outbreaks
  • Continue lifetime in many cases

When ART starts

  • HSV manifestations often improve as immune function returns
  • IRIS (immune reconstitution inflammatory syndrome) can paradoxically worsen HSV temporarily

HSV in transplant patients

Solid organ transplant

  • Reactivation common after transplant
  • Severe outbreaks possible
  • Disseminated infection rare but devastating
  • Prophylaxis often given initially

Hematologic stem cell transplant

  • Higher risk of severe disease
  • Acyclovir prophylaxis routine for first 6-12 months
  • Reactivation can be life-threatening early post-transplant

Standard prophylaxis

  • Acyclovir 400-800 mg twice daily for months
  • Adjusted for kidney function

HSV during chemotherapy

Active chemo

  • HSV reactivation possible
  • Often more severe than baseline
  • Antiviral prophylaxis sometimes used
  • Especially for stem cell rescue or high-dose regimens

After chemo

  • Recovery of immune function over weeks-months
  • HSV pattern may return to baseline
  • Continue suppression if needed

Atypical presentations in immunocompromised

Chronic mucocutaneous ulcers

  • Persistent lesions > 1 month
  • Don't heal completely between outbreaks
  • May extend beyond classic distribution

Disseminated HSV

  • Multiple organ involvement
  • Skin, internal organs
  • Life-threatening
  • Requires hospitalization and IV antivirals

Esophagitis

  • Painful swallowing
  • Common in HIV with low CD4
  • Treated with IV acyclovir, then oral

Retinal involvement (acute retinal necrosis)

  • Rare but vision-threatening
  • Requires urgent ophthalmology
  • IV antivirals

Pneumonitis

  • HSV in lungs
  • Critical illness
  • High mortality

Acyclovir resistance

Who's at risk

  • Severely immunocompromised
  • Stem cell transplant patients
  • Late-stage HIV with multiple HSV treatment courses

How to detect

  • Symptoms not responding to standard treatment
  • Lesions persisting > 7-10 days on full-dose acyclovir
  • Drug susceptibility testing (limited availability)

Treatment of resistant HSV

  • Foscarnet — IV, nephrotoxic but works for most resistant strains
  • Cidofovir — IV or topical, also nephrotoxic
  • Pritelivir — newer drug, may be effective (limited availability)
  • Specialty consultation usually needed

Transmission considerations

Higher risk than immunocompetent

  • More asymptomatic viral shedding
  • Higher viral loads in shed virus
  • Lesions more likely to be infectious

Partner considerations

  • Disclose HSV status
  • Use protective measures
  • Suppressive antivirals reduce transmission
  • Partner risk discussions

Suppressive therapy

Typically recommended

  • Daily acyclovir or valacyclovir
  • May be life-long
  • Higher doses than typical immunocompetent

Standard immunocompromised doses

  • Acyclovir 400-800 mg twice daily
  • Valacyclovir 500-1000 mg twice daily
  • Famciclovir 250-500 mg twice daily
  • Adjust for kidney function

Long-term safety

  • Generally well-tolerated
  • Watch kidney function
  • No major long-term side effects

Special clinical scenarios

Pregnancy + immunocompromise

  • Coordinate OB + ID/immunology
  • Manage suppression aggressively
  • Watch for severe outbreaks
  • Delivery planning per OB

Combination immunocompromise

  • HIV + chemotherapy
  • Transplant + diabetes
  • Multiple risk factors
  • More aggressive prophylaxis
  • ID specialist involvement

Severely immunocompromised (active AIDS, post-transplant)

  • Daily suppression
  • Lower threshold for hospitalization
  • IV therapy when needed
  • Comprehensive ID care

Monitoring

Routine

  • Outbreak frequency and severity
  • Antiviral adherence
  • Renal function (for medication dosing)
  • HIV viral load and CD4 if applicable
  • General immune status

When to test for resistance

  • Symptoms not improving on standard treatment
  • New severe outbreak in established suppression
  • Atypical pattern

What to do if you're immunocompromised + HSV

Get connected to specialty care

  • Infectious disease consultation
  • Continuing care with specialist
  • Coordinate with primary HIV/transplant/oncology provider

Take suppressive therapy

  • Don't skip doses
  • Set reminders
  • Talk to provider about long-term plan

Watch for severe disease signs

  • Multiple lesions in unusual locations
  • Lesions extending beyond normal area
  • Severe pain
  • Fever
  • Multiple body systems involved
  • Difficulty swallowing
  • Eye involvement

Quick action for severe outbreak

  • Don't wait
  • Contact ID provider same day
  • May need hospitalization
  • IV therapy if oral isn't enough

Mental health considerations

What if your provider doesn't know enough about HSV

  • Request infectious disease referral
  • HIV-specialty clinics often have expertise
  • Specialized HSV clinics in major medical centers
  • Telemedicine ID consultations available

Bottom line

HSV in immunocompromised patients:

  • More frequent and severe outbreaks
  • Atypical presentations possible
  • Resistance more common
  • Disseminated disease rare but serious
  • Suppressive antiviral often recommended life-long
  • Specialist care valuable

If you're immunocompromised and have HSV, get connected to specialty care. Continue suppression. Watch for severe disease signs. Modern management makes most cases manageable.

For more, see valacyclovir vs acyclovir, HSV-1 vs HSV-2, herpes outbreak triggers, and our herpes pillar guide.